[1]姚 征,陈玉堂,罗 君,等.131I美妥昔单抗注射液联合TACE治疗76例中晚期原发性肝癌的疗效及安全性研究[J].介入放射学杂志,2016,(01):65-69.
 YAO Zheng,CHEN Yu- tang,LUO Jun,et al.131I- labeled metuximab combined with transcatheter arterial chemoembolization for advanced primary hepatic carcinomas: evaluation of safety and effect in 76 patients[J].journal interventional radiology,2016,(01):65-69.
点击复制

131I美妥昔单抗注射液联合TACE治疗76例中晚期原发性肝癌的疗效及安全性研究 ()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2016年01期
页码:
65-69
栏目:
临床研究
出版日期:
2016-01-25

文章信息/Info

Title:
131I- labeled metuximab combined with transcatheter arterial chemoembolization for advanced primary hepatic carcinomas: evaluation of safety and effect in 76 patients
作者:
姚 征 陈玉堂 罗 君 邵国良 郑家平 曾 晖 郝伟远
Author(s):
YAO Zheng CHEN Yu- tang LUO Jun SHAO Guo- liang ZHENG Jia- ping ZENG Hui HAO Wei- yuan
(收稿日期:2015-06-19)
(本文编辑:俞瑞纲)
关键词:
【关键词】 原发性肝癌 经肝动脉化疗栓塞术 131I美妥昔单抗
文献标志码:
A
摘要:
【摘要】 目的 评价131I美妥昔单抗注射液(利卡汀)联合TACE治疗中晚期原发性肝癌的疗效及安全性。方法 收集2010年11月至2013年5月期间收治的76例原发性肝癌患者,按治疗意愿分为单抗组(美妥昔单抗联合TACE治疗)及对照组(单纯TACE治疗)各38例。入组患者按要求行介入治疗,并定期随访,以评估疗效及不良反应。随访截止日期为2015年3月或肿瘤出现进展。结果 单抗组与对照组相比:1个月临床缓解率分别为23.7%和18.4%;疾病控制率分别为92.1%及97.4%;疾病中位无进展生存期(mPFS)为6个月及8个月,两组间差异无统计学意义(P>0.05)。两组间治疗相关的不良反应基本相仿,而在血液毒性及肝功能损害方面,试验组较对照组更为明显,但多为一过性,未发生与治疗药物相关的严重不良事件。结论 对于中晚期原发性肝癌,美妥昔单抗联合TACE治疗安全性高,但疗效尚需进一步验证。

参考文献/References:

[1] 中华人民共和国卫生部. 原发性肝癌诊疗规范(2011年版)[J].临床肝胆病杂志, 2011, 16: 1141- 1159.
[2] Bruix J, Sherman M. Management of hepatocellular carcinoma[J]. Hepatology, 2005, 42: 1208- 1236.
[3] Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30: 52- 60.
[4] He B, Mao C, Ru B, et al. Epitope mapping of metuximab on CD147 using phage display and molecular docking[J]. Comput Math Methods Med, 2013, 2013: 983829.
[5] Bian H, Zheng JS, Nan G, et al. Randomized trial of 131I metuximab in treatment of hepatocellular carcinoma after percu- taneous radiofrequency ablation[J]. J Natl Cancer Inst, 2014, 106. pii: dju 239.
[6] Li Z, Zhou JX, Ren JZ, et al. Clinical value of 131I metuximab infusion combined with TACE for treatment of patients with post- intervention relapse of mid or advanced stage hepatocellular carcinoma[J]. Zhonghua Gan Zang Bing Za Zhi, 2013, 21: 728- 733.
[7] He Q, Lu WS, Liu Y, et al. 131I labeled metuximab combined with chemoembolization for unresectable hepatocellular carcinoma[J]. World J Gastroenterol, 2013, 19: 9104- 9110.
[8] Dai D, Xu W, Liu J, et al. Safety and efficacy of a peripheral intravenous bolus of Licartin for the treatment of advanced hepatocellular carcinoma[J]. Exp Ther Med, 2013, 6: 1417- 1422.
[9] Xu J, Shen ZY, Chen XG, et al. A randomized controlled trial of Licartin for preventing hepatoma recurrence after liver transplan- tation[J]. Hepatology, 2007, 45: 269- 276.
[10] Zhang Y, Fang L, Zhang Q, et al. An oncolytic adenovirus regulated by a radiation- inducible promoter selectively mediates hSulf- 1 gene expression and mutually reinforces antitumor activity of 131I metuximab in hepatocellular carcinoma[J]. Mol Oncol, 2013, 7: 346- 358.
[11] 许国辉, 张智慧, 李政文, 等. 131I肝癌单抗片段HAb18F(ab)2灌注治疗原发性肝癌的临床研究[J]. 介入放射学杂志,2005, 14: 596- 598.

相似文献/References:

[1]高 嵩,朱旭,杨仁杰,等. TACE联合奥沙利铂、氟尿嘧啶、亚叶酸钙肝动脉化疗治疗中晚期原发性肝癌[J].介入放射学杂志,2012,(05):377.
 ,,et al. TACE combined with hepatic arterial infusion chemotherapy using oxaliplatin, 5fluorouracil and folinic acid for intermediate and advanced hepatocellular carcinomas[J].journal interventional radiology,2012,(01):377.
[2]程洪涛,郭晨阳,黎海亮,等.TACE联合射频消融治疗原发性肝癌疗效的影响因素分析[J].介入放射学杂志,2012,(03):216.
 ,,et al.TACE combined with CTguided percutaneous radiofrequency ablation for the treatment of primary hepatocellular carcinomas: an analysis of factors affecting the therapeutic result [J].journal interventional radiology,2012,(01):216.
[3]张晓前,郭 鹏,党之俊,等.金龙胶囊联合介入疗法治疗原发性肝癌临床观察[J].介入放射学杂志,2012,(03):249.
 ,,et al.Kinglong capsules combined with interventional therapy for hepatocellular carcinomas: clinical observation [J].journal interventional radiology,2012,(01):249.
[4]姚红响,陈根生,诸葛英,等.肝动脉化疗栓塞联合CT引导射频消融序贯治疗中小肝癌的临床应用[J].介入放射学杂志,2012,(04):301.
 ,,et al.Sequential treatment with TACE and CTguided RFA for small and moderate sized HCC [J].journal interventional radiology,2012,(01):301.
[5]姚全军,胡鸿涛,黎海亮,等.C臂CT成像在乏血供原发性肝癌诊疗中的临床应用[J].介入放射学杂志,2012,(04):305.
 ,,et al.The clinical application of C arm CT imaging in diagnosing and treating hypovascular primary hepatic carcinomas [J].journal interventional radiology,2012,(01):305.
[6]刘 昕,吕维富,鲁 东,等. 动脉介入栓塞治疗肝癌破裂出血[J].介入放射学杂志,2012,(07):586.
 LIU Xin,LV Wei- fu,LU Dong,et al. Interventional treatment of hepatic bleeding due to spontaneous rupture of hepatocellular carcinoma[J].journal interventional radiology,2012,(01):586.
[7]张志良,杨学东,温阿明,等. 经动脉化疗栓塞联合伽玛刀治疗原发性肝癌的疗效评价[J].介入放射学杂志,2012,(07):596.
 ZHANG Zhi- liang,YANG Xue- dong,WEN A-ming,et al. Evaluation of TACE combined with gamma?蛳 knife radiotherapy for primary hepatocellular carcinoma[J].journal interventional radiology,2012,(01):596.
[8]赵许亚,周 石.TACE联合经皮瘤内注射碘油吡柔比星乳剂治疗中晚期肝癌疗效分析[J].介入放射学杂志,2012,(08):675.
 ZHAO Xu- ya,ZHOU Shi.. Transcatheter artery chemoembolization combined with percutaneous intratumoral injection of Lipiodol emulsion of pirarubicin for advanced hepatocellular carcinomas: an analysis of clinical efficacy[J].journal interventional radiology,2012,(01):675.
[9]王少雷,李 森,魏 宏,等.奥沙利铂与吡喃阿霉素介入治疗原发性肝癌的比较研究[J].介入放射学杂志,2012,(09):738.
 WANG Shao- lei,LI Sen,WEI Hong,et al. Interventional chemoembolization therapy of primary hepatocellular carcinoma: a comparative study between oxaliplatin and therarubicin[J].journal interventional radiology,2012,(01):738.
[10]骆俊朋,胡鸿涛,郭晨阳,等.吉西他滨热化疗灌注联合卡铂化疗栓塞治疗原发性肝癌临床应用研究[J].介入放射学杂志,2013,(06):470.
 LUO Jun? peng,HU Hong? tao,GUO Chen? yang,et al. Hyperthermochemotherapy by using heated gemcitabine perfusion combined with transcatheter arterial chemoembolization of carboplatin for primary liver carcinomas[J].journal interventional radiology,2013,(01):470.
[11]王文辉,李宝华,李 雷,等.载药微球治疗中期原发性肝癌25例[J].介入放射学杂志,2021,30(03):270.
 WANG Wenhui,LI Baohua,LI Lei,et al.CalliSpheres-loaded microspheres for the treatment of mid-stage hepatocellular carcinoma: analysis of its efficacy and safety in 25 patients[J].journal interventional radiology,2021,30(01):270.
[12]曹莉明,张勇学,梁志会,等.不同方式联合TACE治疗原发性肝癌合并上消化道出血的临床疗效[J].介入放射学杂志,2024,33(01):33.
 CAO Liming,ZHANG Yongxue,LIANG Zhihui,et al.Different therapeutic methods combined with TACE for primary liver cancer complicated by upper gastrointestinal bleeding: evaluation of clinical efficacy[J].journal interventional radiology,2024,33(01):33.

备注/Memo

备注/Memo:
(收稿日期:2015-06-19)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2016-01-22